Bispecific antibody

A bispecific antibody targeting IL-18 and IL-23 addresses the limitations of current therapies by simultaneously modulating both cytokine pathways, providing effective control of inflammation and improving treatment outcomes for chronic diseases.

WO2026234381A1PCT designated stage Publication Date: 2026-11-12APOLLO THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2026/050778
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapies targeting either IL-18 or IL-23 fail to achieve durable remission in complex or refractory inflammatory diseases, highlighting the need for a therapeutic approach that can simultaneously modulate both cytokine pathways to control inflammation effectively.

Method used

A bispecific antibody designed to bind and neutralize both IL-18 and IL-23, inhibiting their pathways in a coordinated manner, potentially reducing excessive inflammation and alleviating symptoms of chronic diseases such as inflammatory bowel disease and chronic inflammatory skin diseases.

Benefits of technology

The dual targeting approach offers superior clinical outcomes compared to monoclonal antibodies, minimizing adverse effects and improving treatment efficacy and safety by restoring immune balance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GB2026050778_12112026_PF_FP_ABST
    Figure GB2026050778_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to bispecific antibodies, and particularly to antibodies that specifically bind to IL-18 and IL-23. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis. More specifically, the invention pertains to a bispecific antibody that targets IL-18 and IL-23 and can be used for the treatment of diseases associated with excessive or dysregulated IL-18 and IL-23 activity, including inflammatory bowel disease and chronic inflammatory skin diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Bispecific Antibody

[0002] The invention relates to bispecific antibodies, and particularly to antibodies that specifically bind to IL-18 and IL-23. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis. More specifically, the invention pertains to a bispecific antibody that targets IL-18 and IL-23 and can be used for the treatment of diseases associated with excessive or dysregulated IL-18 and IL-23 activity, including inflammatory bowel disease and chronic inflammatory skin diseases.

[0003] Inflammatory and autoimmune diseases are often characterized by dysregulated immune responses involving multiple cytokine pathways. Among these, interleukin-18 (IL-18) and interleukin-23 (IL-23) have independently emerged as critical drivers of chronic inflammation, immune cell activation, and tissue damage in a range of pathological conditions.

[0004] IL-18 is a member of the IL-1 cytokine family and is produced by activated macrophages, epithelial cells, and other immune cells following inflammasome activation. It plays a key role in the induction of interferon-y (IFN-y) and the promotion of Thl immune responses, while also contributing to macrophage activation, NK cell cytotoxicity, and systemic inflammation (Landy et al., 2024 and Wang et al., 2023).

[0005] IL-23, in contrast, is a key cytokine involved in the expansion and maintenance of Thl7 cells, promoting production of IL-17 and IL-22 and driving inflammation at barrier tissues such as the skin, joints, and gastrointestinal tract. IL-23 has been strongly implicated in chronic immune-mediated diseases including psoriasis, psoriatic arthritis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, and is a validated therapeutic target with several IL-23pl9 inhibitors currently approved or in development (Gaffen et al, 2014).

[0006] Although IL-18 and IL-23 are traditionally associated with distinct immune pathways (Thl and Thl7, respectively), emerging evidence suggests pathogenic convergence in several diseases, particularly in those with mixed or evolving inflammatory phenotypes. For example, elevated levels of both IL-18 and IL-23 have been observed in subsets of patients with inflammatory bowel disease, systemic lupus erythematosus, and chronic inflammatory skin diseases.Despite the availability of monotherapies targeting either IL-18 or IL-23, many patients with complex or refractory disease fail to achieve durable remission. This highlights an unmet clinical need for therapies capable of simultaneously modulating multiple inflammatory pathways in a targeted manner (Shimoura et al., 2017).

[0007] To address this need, the present invention relates to a bispecific antibody that simultaneously targets IL-18 and IL-23, offering a novel therapeutic strategy to inhibit both cytokines in a coordinated and efficient manner. By blocking IL-18-mediated Thl / macrophage activation and IL-23-mediated Thl7 expansion, this bispecific approach aims to provide superior control of inflammation in diseases where both pathways are pathogenic. Furthermore, the dual targeting format may reduce the need for combination biologic therapy, potentially improving treatment efficacy, safety, and convenience for patients.

[0008] There is, therefore, the need for improved compositions for targeting IL-18 and IL-23 and treating diseases mediated by these two cytokines.

[0009] This invention pertains to a novel IL-18 / IL-23 bispecific antibody designed to bind and neutralize both IL-18 and IL-23. By targeting both cytokines, the antibody has the potential to reduce excessive inflammation, alleviate symptoms of chronic diseases such as inflammatory bowel disease and chronic inflammatory skin diseases, and restore immune balance. The dual targeting approach may offer superior clinical outcomes compared to monoclonal antibodies targeting either cytokine alone, while minimizing the risk of adverse effects associated with off-target activity. In addition to its therapeutic potential in inflammatory bowel disease and chronic inflammatory skin diseases, this bispecific antibody may have broader applications in other inflammatory diseases and autoimmune conditions, where dysregulation of IL-18 and IL-23 contributes to disease pathology.

[0010] Accordingly, in a first aspect of the invention, there is provided a bispecific antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to Interleukin-18 (IL-18) or a functional fragment or variant thereof, and a second antigen-binding domain that specifically binds to Interleukin-23 (IL-23) or a functional fragment or variant thereof.

[0011] As shown in the Examples, the inventors have developed bispecific antibodies that are capable of binding to IL-18 and IL-23, or a functional fragment or variant thereof, and inhibiting IL-18 and IL-23 function. The six CDR, VH, VL, CH and CL sequences of thefirst (IL-18) and second (IL-23) antigen-binding domains are summarised in the table shown in Figure 12. The inventors have used several different technologies to generate these bispecific antibodies, including controlled Fab-arm exchange (cFAE), Duobody, CrossMab, and WuxiBody. Accordingly, with reference to Figure 12, the bispecific antibodies according to the invention are generated as follows: (i) "Al" IL-18 antigen binding domain (duobody) paired with "Bl" IL-23 antigen binding domain (duobody); (ii) "A2" IL-18 antigen binding domain (CrossMab regular arm) paired with "B2" IL-23 antigen binding domain (CrossMab cross arm); (iii) "A3" IL-18 antigen binding domain (CrossMab cross arm) paired with "B3" IL-23 antigen binding domain (CrossMab regular arm); (iv) "A4" IL-18 antigen binding domain (WuxiBody regular arm) paired with "B4" IL-23 antigen binding domain (WuxiBody Wuxi arm); and (v) "A5" IL-18 antigen binding domain (WuxiBody Wuxi arm) paired with "B5" IL-23 antigen binding domain (WuxiBody regular arm).

[0012] The invention extends to both whole antibodies (i.e. immunoglobulins) with immunospecificity for IL-18 and IL-23, or functional fragments or variants thereof, as well as to antigen-binding fragments or regions of the corresponding full-length antibody.

[0013] The antibody or antigen-binding fragment thereof may be monovalent, divalent or polyvalent. Monovalent antibodies are dimers (HL) comprising a heavy (H) chain associated by a disulphide bridge with a light chain (L). Divalent antibodies are tetramer (H2L2) comprising two dimers associated by at least one disulphide bridge. Polyvalent antibodies may also be produced, for example by linking multiple dimers. The basic structure of an antibody molecule consists of two identical light chains and two identical heavy chains which associate non-covalently and can be linked by disulphide bonds. Each heavy and light chain contains an amino-terminal variable region of about 110 amino acids, and constant sequences in the remainder of the chain. The variable region includes several hypervariable regions, or Complementarity Determining Regions (CDRs), that form the antigen-binding site of the antibody molecule and determine its specificity for the antigen, i.e. IL-18 and IL-23 (e.g. an epitope). On either side of the CDRs of the heavy and light chains is a framework region, a relatively conserved sequence of amino acids that anchors and orients the CDRs. Antibody fragments may include a bi-specific antibody (BsAb) or a chimeric antigen receptor (CAR).

[0014] The heavy chain constant region typically comprises three domains, CHI, CH2, and CHS. Each light chain typically comprises a light chain variable region (VL) and a light chainconstant region. The light chain constant region typically comprises one domain, abbreviated CL.

[0015] Each heavy chain and light chain generally comprise three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 -CDR2 - FR3 - CDR3 - FR4. The CDRs are involved in antigen binding and confer antigen specificity and binding affinity to the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference in its entirety.

[0016] The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated a, 6, e, y, and p, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2. In one embodiment, the antibody is of the IgG antibody class. In one embodiment, the antibody is of the IgGl antibody class.

[0017] The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.

[0018] The constant region consists of one of five heavy chain sequences (p, y,

[0019]

[0020] a, or e) and one of two light chain sequences (K or A). The heavy chain constant region sequences determine the isotype of the antibody and the effector functions of the molecule.

[0021] In some embodiments, the antibody or antigen-binding fragment thereof is isolated or purified.

[0022] In one embodiment, the antibody or antigen-binding fragment thereof comprises a polyclonal antibody, or an antigen-binding fragment thereof. The antibody or antigenbinding fragment thereof may be generated in a rabbit, mouse or rat.

[0023] In another embodiment, the antibody or antigen-binding fragment thereof comprises a monoclonal antibody or antigen-binding fragment thereof. In some embodiments, the antibody of the invention is a human antibody. As used herein, the term "human antibody" can mean an antibody, such as a monoclonal antibody, which comprises substantially the same heavy and light chain CDR amino acid sequences as found in a particular human antibody exhibiting immunospecificity for IL-18 or IL-23, or a variantor fragment thereof. An amino acid sequence, which is substantially the same as a heavy or light chain CDR, exhibits a considerable amount of sequence identity when compared to a reference sequence. Such identity is definitively known or recognizable as representing the amino acid sequence of the particular human antibody.

[0024] Substantially the same heavy and light chain CDR amino acid sequence can have, for example, minor modifications or conservative substitutions of amino acids. Such a human antibody maintains its function of selectively binding to IL-18 or IL-23, or a variant or fragment thereof.

[0025] The term "human monoclonal antibody" can include a monoclonal antibody with substantially or entirely human CDR amino acid sequences produced, for example by recombinant methods such as production by a phage library, by lymphocytes or by hybridoma cells.

[0026] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (by so-called "affinity maturation"), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.

[0027] The term "humanised antibody" can mean an antibody from a non-human species (e.g. mouse or rabbit) whose protein sequences have been modified to increase their similarity to antibodies produced naturally in humans.

[0028] The antibody may be a recombinant antibody. The term "recombinant human antibody" can include a human antibody produced using recombinant DNA technology.

[0029] The term "antigen-binding region" can mean a region of the antibody having specific binding affinity for its target antigen, for example, IL-18 and IL-23, or variants or fragments thereof. In some embodiments, the fragment is an epitope. The antigen-binding region may be a hypervariable CDR or a functional portion thereof. The term "functional portion" of a CDR can mean a sequence within the CDR which shows specific affinity for the target antigen. The functional portion of a CDR may comprise a ligand which specifically binds to IL-18 and IL-23, or variants or fragments thereof.

[0030] The term "CDR" can mean a hypervariable region in the heavy and light variable chains. There may be one, two, three or more CDRs in each of the heavy and light chains of the antibody. Normally, there are at least three CDRs on each chain which, when configured together, form the antigen-binding site, i.e. the three-dimensional combining site with which the antigen binds or specifically reacts. It has however been postulated that there may be four CDRs in the heavy chains of some antibodies.

[0031] The definition of CDR also includes overlapping or subsets of amino acid residues when compared against each other. The exact residue numbers which encompass a particular CDR or a functional portion thereof will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

[0032] The amino acid sequence boundaries of a CDR can be determined by using any of a number of known numbering schemes, including those described by Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 ("Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 ("AHo" numbering scheme).

[0033] The term "functional fragment" of an antibody can mean a portion of the antibody which retains a functional activity. A functional activity can be, for example, antigen binding activity or specificity. A functional activity can also be, for example, an effector function provided by an antibody constant region. The term "functional fragment" is also intended to include, for example, fragments produced by protease digestion or reduction of a human monoclonal antibody and by recombinant DNA methods known to those skilled in the art. Human monoclonal antibody functional fragments include, for example individual heavy or light chains and fragments thereof, such as VL, VH and Fd; monovalent fragments, such as Fv, Fab, and Fab'; bivalent fragments such as F(ab')2; single chain Fv (scFv); bivalent or trivalent scFvs, scFv-Fc-scFv, an IgG-scFv, an IgG-dAb, KIH-IgG, KX-BODY, KIH-FC Fab / scFv, tri / tetraspecific, KIH tri / tetra-specific, or a tandem scFv, and Fc fragments. The Fc fragment of the antibody may be disabled by introducing amino acid substitutions into the Fc region, which silence or reduce the effector function of the antibody.

[0034] The term "VL fragment" can mean a fragment of the light chain of a human monoclonal antibody which includes all or part of the light chain variable region, including the CDRs. A VL fragment can further include light chain constant region sequences.

[0035] The term "VH fragment" can mean a fragment of the heavy chain of a human monoclonal antibody which includes all or part of the heavy chain variable region, including the CDRs.

[0036] The term "Fd fragment" can mean the heavy chain variable region coupled to the first heavy chain constant region, i.e. VH and CH-1. The "Fd fragment" does not include the light chain, or the second and third constant regions of the heavy chain.

[0037] The term "Fv fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody, including all or part of the variable regions of the heavy and light chains, and absent of the constant regions of the heavy and light chains. The variable regions of the heavy and light chains include, for example, the CDRs. For example, an Fv fragment includes all or part of the amino terminal variable region of about 110 amino acids of both the heavy and light chains.

[0038] The term "Fab fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than an Fv fragment. For example, a Fab fragment includes the variable regions, and all or part of the first constant domain of the heavy and light chains. Thus, a Fab fragment additionally includes, for example, amino acid residues from about 110 to about 220 of the heavy and light chains.

[0039] The term "Fab' fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than a Fab fragment. For example, a Fab' fragment includes all of the light chain, all of the variable region of the heavy chain, and all or part of the first and second constant domains of the heavy chain. For example, a Fab' fragment can additionally include some or all of amino acid residues 220 to 330 of the heavy chain.The term "F(ab')2 fragment" can mean a bivalent antigen-binding fragment of a human monoclonal antibody. An F(ab')2 fragment includes, for example, all or part of the variable regions of two heavy chains-and two light chains, and can further include all or part of the first constant domains of two heavy chains and two light chains.

[0040] The term "single chain Fv (scFv)" can mean a fusion of the variable regions of the heavy (VH) and light chains (VL) connected with a short linker peptide.

[0041] One skilled in the art knows that the exact boundaries of a fragment of an antibody are not important, so long as the fragment maintains a functional activity. Using well-known recombinant methods, one skilled in the art can engineer a polynucleotide sequence to express a functional fragment with any endpoints desired for a particular application. A functional fragment of the antibody may comprise or consist of a fragment with substantially the same heavy and light chain variable regions as the human antibody.

[0042] Typically, the antigen-binding fragment thereof, with respect to the first aspect of the invention, are immunospecific for IL-18 or IL-23, or a functional fragment or variant thereof. The antigen-binding fragment thereof may comprise or consist of any of the fragments selected from a group consisting of VH, VL, Fd, Fv, Fab, Fab', scFv, F (ab')2 and Fc fragment.

[0043] The antigen-binding fragment thereof may be a single domain antibody (sdAb), otherwise referred to as a nanobody, which the skilled person would understand is an antibody fragment consisting of a single monomeric variable antibody domain.

[0044] The antigen-binding fragment thereof may comprise or consist of any one of the antigen binding region sequences of the VL, any one of the antigen binding region sequences of the VH, or a combination of VL and VH antigen binding regions of a human antibody. The appropriate number and combination of VH and VL antigen binding region sequences may be determined by those skilled in the art depending on the desired affinity and specificity and the intended use of the antigen-binding fragment. Functional fragments or antigen-binding fragments of antibodies may be readily produced and isolated using methods well known to those skilled in the art. Such methods include, for example, proteolytic methods, recombinant methods and chemical synthesis. Proteolytic methods for the isolation of functional fragments comprise using human antibodies as a starting material. Enzymes suitable for proteolysis of human immunoglobulins may include, for example, papain, and pepsin.The appropriate enzyme may be readily chosen by one skilled in the art, depending on, for example, whether monovalent or bivalent fragments are required. For example, papain cleavage results in two monovalent Fab' fragments that bind antigen and an Fc fragment. Pepsin cleavage, for example, results in a bivalent F (ab') fragment. An F (ab')2 fragment of the invention may be further reduced using, for example, DTT or 2-mercaptoethanol to produce two monovalent Fab' fragments.

[0045] Functional or antigen-binding fragments of antibodies produced by proteolysis may be purified by affinity and column chromatographic procedures. For example, undigested antibodies and Fc fragments may be removed by binding to protein A. Additionally, functional fragments may be purified by virtue of their charge and size, using, for example, ion exchange and gel filtration chromatography. Such methods are well known to those skilled in the art.

[0046] The antibody or antigen-binding fragment thereof may be produced by recombinant methodology. In some embodiments, one initially isolates a polynucleotide encoding desired regions of the antibody heavy and light chains. Such regions may include, for example, all or part of the variable region of the heavy and light chains. In some embodiments, such regions can particularly include the antigen binding regions of the heavy and light chains, typically the antigen binding sites, most typically the CDRs.

[0047] The polynucleotide encoding the bispecific antibody or antigen-binding fragment thereof according to the invention may be produced using methods known to those skilled in the art. The polynucleotide encoding the bispecific antibody or antigenbinding fragment thereof may be directly synthesized by methods of oligonucleotide synthesis known in the art. Alternatively, smaller fragments may be synthesized and joined to form a larger functional fragment using recombinant methods known in the art.

[0048] As used herein, the term "immunospecificity" can mean the binding region of the bispecific antibody or antigen-binding fragment thereof is capable of immunoreacting with IL-18 and IL-23, by specifically binding therewith. In some embodiments, the bispecific antibody or antigen-binding fragment thereof can selectively interact with an antigen (i.e. IL-18 and IL-23) with an affinity constant of approximately 10'5to 10'13M’1, or IO’6to IO’9M’1, or IO’10to IO’12M’1.The term "immunoreact" can mean the binding region is capable of eliciting an immune response upon binding with IL-18 and IL-23, or an epitope thereof.

[0049] The term "epitope" can mean any region of an antigen with the ability to elicit, and combine with, a binding region of the bispecific antibody or antigen-binding fragment thereof. The epitope may be linear. This can mean that the antibody interacts with a plurality of continuous amino acids of the antigen, and so the epitope can consist of these defined amino acids. Alternatively, the epitope may be conformational, i.e. nonlinear or discontinuous. This can mean that the antibody interacts with multiple, distinct segments from the primary amino acid sequence of the antigen.

[0050] Thus, the bispecific antibody or antigen-binding fragment thereof may comprise a heavy chain. The heavy chain may be selected from the group consisting of IgA; IgD; IgE; IgG and IgM. In some embodiments, the heavy chain is an IgA. In some embodiments, the heavy chain is an IgG.

[0051] The heavy chain may be an IgGl. The heavy chain may be an IgG2. The heavy chain may be an IgG3. The heavy chain may be an IgG4. The heavy chain may be an IgAl. The heavy chain may be an IgA2.

[0052] In some embodiments, the bispecific antibody is a heterodimeric antibody. In some embodiments, the bispecific antibody is derived from two monoclonal antibodies (mAbs), an anti-IL-18 mAb or antigen-binding fragment thereof, and an anti-IL-23 mAb or antigen-binding fragment thereof. In some embodiments, the anti-IL-18 mAb or antigen-binding fragment thereof contributes to the first antigen-binding domain binding to IL-18 in the bispecific antibody. In some embodiments, the anti-IL-23 mAb or antigen-binding fragment thereof contributes to the second antigen-binding domain binding to IL-23 in the bispecific antibody. In some embodiments, each of these mAbs contributes one distinct heavy (H) chain and one distinct light (L) chain to the bispecific antibody, resulting in four chains in the bispecific antibody. In some embodiments, the four chains in the bispecific antibody are covalently linked via five inter-chain disulfide bonds.

[0053] In some embodiments, the bispecific antibody comprises: a) a first antigen-binding domain comprising a first light chain variable domain (VL1) and a first heavy chain variable domain (VH1), that binds specifically to IL-18 or a functional fragment or variant thereof, and b) a second antigen-binding domain comprising a second lightchain variable domain (VL2) and a second heavy chain variable domain (VH2), that binds specifically to IL-23 or a functional fragment or variant thereof.

[0054] In some embodiments, the first antigen-binding domain comprises an IL-18 scFv or an IL-18 Fab. In some embodiments, the first antigen-binding domain comprises one or two IL-18 Fabs.

[0055] In some embodiments, the second antigen-binding domain comprises an IL-23 scFv or an IL-23 Fab. In some embodiments, the second antigen-binding domain comprises one or two IL-23 Fabs.

[0056] In some embodiments, the first antigen-binding domain comprises an IL-18 scFv and the second antigen-binding domain comprises an IL-23 scFv. In some embodiments, the two scFv are linked to each other by a shorter linked peptide.

[0057] In some embodiments, the first and second antigen-binding domains of the bispecific antibody or antigen-binding fragment thereof are linked. In some embodiments, that linkage is a direct linkage, and the regions are fused to each other. In some embodiments, the first binding domain and / or the second binding domain are fused to a Fc polypeptide chain. In some embodiments, the second binding domain (e.g. IL-23 Fab) is linked, e.g., via a polypeptide linker, to the N-terminus of the first binding domain. In some embodiments, the second binding domain (e.g. IL-23 Fab) is linked, e.g., fused, to the N-terminus of the first binding domain.

[0058] Protocols for generating bispecific antibodies are known in the art; including but not limited to, for example, the "knob in a hole" approach; the electrostatic steering Fc pairing; Strand Exchange Engineered Domains (SEED) heterodimer formation; Fab arm exchange; double antibody conjugate, e.g., by antibody cross-linking to generate a bi-specific structure using a heterobifunctional reagent having an amine-reactive group and a sulfhydryl reactive group; bispecific antibody or antibody-like molecule determinants generated by recombining half antibodies (heavy-light chain pairs or Fabs) from different antibodies or antibody-like molecules through cycle of reduction and oxidation of disulfide bonds between the two heavy chains; trifunctional antibodies, e.g., three Fab' fragments cross-linked through sulfhydryl reactive groups; biosynthetic binding proteins, e.g., pair of scFvs cross-linked through C-terminal tails preferably through disulfide or amine-reactive chemical cross-linking; bifunctional antibodies, e.g., Fab fragments with different binding specificities dimerized through leucine zippers that have replaced the constant domain; bispecific and oligospecificmono-and oligovalent receptors, e.g., VH-CH1 regions of two antibodies (two Fab fragments) linked through a polypeptide spacer between the CHI region of one antibody and the VH region of the other antibody typically with associated light chains; bispecific DNA-antibody conjugates, e.g., crosslinking of antibodies or Fab fragments through a double stranded piece of DNA; bispecific fusion proteins, e.g., an expression construct containing two scFvs with a hydrophilic helical peptide linker between them and a full constant region; multivalent and multi-specific binding proteins, e.g., dimer of polypeptides having first domain with binding region of Ig heavy chain variable region, and second domain with binding region of Ig light chain variable region, generally termed diabodies (higher order structures are also encompassed creating for bispecific, trispecific, or tetraspecific molecules; minibody constructs with linked VL and VH chains further connected with peptide spacers to an antibody hinge region and CH3 region, which can be dimerized to form bispecific / multivalent molecules; VL and VH domains linked with a short peptide linker (e.g., 5 or 10 amino acids) or no linker at all in either orientation, which can form dimers to form bispecific diabodies; trimers and tetramers; string of VH domains (or VL domains in family members) connected by peptide linkages with crosslinkable groups at the C-terminus further associated with VL domains to form a series of Fvs (or scFvs); VL and VH domains, scFvs, or Fabs wherein one of the antigens is bound monovalently and one of the antigens is bound bivalently, optionally comprising heterodimeric Fc regions; and single chain binding polypeptides with both a VL and VH domain linked through a peptide linker are combined into multivalent structures through non-covalent or chemical crosslinking to form, e.g., homobivalent, heterobivalent, trivalent, and tetravalent structures using both scFv or diabody type format.

[0059] Controlled Fab-arm exchange (cFAE) is the in vitro post-production process in which IgGl half-molecules recombine with other IgGl half-molecules to generate bispecific IgGl antibodies. In particular, this involves the recombination of antigen-binding arms (heavy chain-light chain (H-L) pairs) between individually expressed antibody molecules. This unidirectional reaction takes place under tailored reaction conditions in vitro with IgGl antibodies containing single matched point-mutations in the CH3 domains. To promote Fc heterodimerization, one antibody is engineered with an F405L mutation and the other with a K409R mutation. The two parental antibodies are expressed separately, mixed at equimolar ratios, and subjected to mild reducing conditions to allow Fab-arm exchange. Upon removal of the reducing agent, interheavy chain disulfide bonds reform, stabilizing the heterodimeric bispecific antibody.The DuoBody® biotechnology involves three basic steps to generate stable bispecific human IgGl antibodies. In a first step, two IgGls, each containing single matched mutations in the third constant (CH3) domain (lysine at position 409 to arginine, K409R; phenylalanine at position 405 to leucine, F405L), are produced separately using recombinant mammalian expression systems. These mutations allow the homodimeric, monospecific parental mAbs against different targets to recombine to form a single heterodimeric, bispecific antibody. Subsequently, these IgGl antibodies are purified according to standard processes for recovery and purification. After production and purification (post-production), the two antibodies are recombined using controlled Fab-arm exchange (cFAE), resulting in a bispecific antibody product.

[0060] The basis of the CrossMab technology is the crossover of antibody domains within one arm of a bispecific IgG antibody enabling correct chain association. This can be achieved by exchange of different domains within the Fab-fragment. Either the Fab domains (in the CrossMabFabformat), or only the variable VH-VL domains (CrossMabVH‘VLformat) or the constant CH1-CL domains (CrossMabCH1'CLformat) within the Fab-fragment can be exchanged for this purpose. For example, the Fab arm retains a conventional heavy chain / light chain pairing, and the second arm contains variable domains which have been swapped at the molecular level to promote correct chain pairing. The Fc is engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm.

[0061] WuxiBody technology involves the replacement of one parental mAb's CH1 / CL region by the T cell receptor (TOR) constant domain. WuXiBody's design ensures cognate HC-LC pairing, the same goal as that being aimed by the CrossMab technology. One Fab arm comprises immunoglobulin (IgG) constant domains and the other Fab arm comprises engineered human TCR constant domains (Co / CP), enabling orthogonal heavy / light chain pairing. The Fc is engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm.

[0062] Mispairing and mismatching between light chains and heavy chains can occur when preparing the bispecific antibody or antigen binding fragment thereof. Mispairing refers to the incorrect pairing of heavy and light chains during antibody assembly. Mismatching refers to the presence of different types of antibody chains within a bispecific antibody, even if the chains are correctly paired. This can occur due to genetic or structural variability within the antibody chains, leading to a broaderspectrum of antibody species. Antibodies with mispairing and / or mismatches may have to be separated from the desired bispecific antibodies by purification processes.

[0063] In one embodiment, the amino acid sequence of IL-18 may be provided herein as SEQ ID No: 42, as follows:

[0064] MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLESDYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRT IFI ISMYKDSQPRGMAVTI SVKCEKISTLSCENKI ISFKEMNPPDNIKDTKSDI IFFQRSVPGHDNKMQFESSSYEGYFLA CEKERDLFKLI LKKEDELGDRS IMFTVQNED

[0065] [SEQ ID No: 42]

[0066] Thus, in one embodiment, the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 42, or a functional fragment or variant thereof.

[0067] In one embodiment, the amino acid sequence of IL-23 may be provided herein as SEQ ID No: 43, as follows:

[0068] MNQVTIQWDAVIALYILFSWCHGGITNINCSGHIWVEPATIFKMGMNISIYCQAAIKNCQPRKLHFYKNGIKERFQITRIN KTTARLWYKNFLEPHASMYCTAECPKHFQETLICGKDISSGYPPDIPDEVTCVIYEYSGNMTCTWNAGKLTYIDTKYWHV KSLETEEEQQYLTSS YINI STDSLQGGKKYLVWVQAANALGMEESKQLQIHLDDIVIPSAAVI SRAE TINA TVPKT I I YWD SQTTIEKVSCEMRYKATTNQTWNVKEFDTNFTYVQQSEFYLEPNIKYVFQVRCQETGKRYWQPWSSLFFHKTPETVPQVTS KAFQHDTWNSGLTVASISTGHLTSDNRGDIGLLLGMIVFAVMLSILSLIGIFNRSFRTGIKRRILLLIPKWLYEDIPNMKN SNVVKMLQENSELMNNNSSEQVLYVDPMITEIKEIFIPEHKPTDYKKENTGPLETRDYPQNSLFDNTTVVYIPDLNTGYKP QISNFLPEGSHLSNNNEITSLTLKPPVDSLDSGNNPRLQKHPNFAFSVSSVNSLSNTIFLGELSLILNQGECSSPDIQNSV EEETTMLLENDSPSETIPEQTLLPDEFVSCLGIVNEELPSINTYFPQNILESHFNRISLLEK

[0069] [SEQ ID No: 43]

[0070] Thus, in one embodiment, the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 43, or a functional fragment or variant thereof.

[0071] It will be appreciated that "functional fragment or variant thereof" refers to fragments and variants of IL-18 and / or IL-23 that retain at least part of the activity of IL-18 and / or IL-23.

[0072] As described in the Examples, the inventors have surprisingly demonstrated that the bispecific antibodies or antigen-binding fragments referred to herein, are able to significantly target IL-18 and IL-23, or functional fragments or variants thereof, and each of these antibodies are defined below in detail. The CDR, VH, VL, CH and CLsequences of these antibodies are conveniently summarised in the table shown in Figure 12. The sequences are provided using Kabat, Chothia, IMGT and Combined numbering schemes.

[0073]

[0074] Al-Bl (IL-18 / IL-23

[0075] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as Al-Bl.

[0076] First antigen-binding domain (IL-18)

[0077] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.

[0078] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.

[0079] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.

[0080] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.

[0081] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.

[0082] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.

[0083] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.

[0084] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.

[0085] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0086] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0087] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.

[0088] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0089] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0090] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0091] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0092] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.

[0093] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 17, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.

[0094] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 17 and a light chain constant region comprising or consisting of SEQ ID No: 21.

[0095] Second antigen-binding domain (IL-23)

[0096] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27, 29 or 32, or a variant or fragment thereof.

[0097] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.

[0098] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.

[0099] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27, 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.

[0100] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27, a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.

[0101] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.

[0102] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.

[0103] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.

[0104] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0105] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0106] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.

[0107] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0108] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0109] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0110] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0111] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0112] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 41, or a variant or fragment thereof.

[0113] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.

[0114] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 41 and a light chain constant region comprising or consisting of SEQ ID No: 21.

[0115] A2-B2 (IL-18 CrossMab Regular Arm / IL-23 CrossMab Cross Arm)

[0116] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A2-B2.

[0117] First antigen-binding domain (IL-18)

[0118] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.

[0119] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.

[0120] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.

[0121] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.

[0122] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.

[0123] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.

[0124] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.

[0125] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.

[0126] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.

[0127] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0128] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.

[0129] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0130] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0131] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0132] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0133] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.

[0134] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.

[0135] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.

[0136] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.

[0137] Second antigen-binding domain (IL-23)

[0138] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.

[0139] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.

[0140] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.

[0141] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35.

[0142] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domaincomprising or consisting of SEQ ID No: 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 37 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35.

[0143] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.

[0144] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 , 29 or 32, or a variant or fragment thereof.

[0145] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.

[0146] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.

[0147] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.

[0148] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 27 , a CDR-L2 domain comprising or consisting of SEQ ID No: 28, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 29, a CDR-L2 domain comprising or consisting of SEQ ID No: 30, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 31.In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.

[0149] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0150] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27, 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.

[0151] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.

[0152] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 27 , a CDR-L2 domain comprising or consisting of SEQ ID No: 28, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.

[0153] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 29, a CDR-L2 domain comprising or consisting of SEQ ID No: 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 31.

[0154] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consistingof SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 31.

[0155] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 39, and a light chain variable region comprising or consisting of SEQ ID No: 38.

[0156] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 19, or a variant or fragment thereof.

[0157] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 22, or a variant or fragment thereof.

[0158] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 19 and a light chain constant region comprising or consisting of SEQ ID No: 22.

[0159] A3-B3 (IL-18 CrossMab Cross Arm / IL-23 CrossMab Regular Arm)

[0160] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A3-B3.

[0161] First antigen-binding domain (IL-18)

[0162] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.

[0163] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.

[0164] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 or 13 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11.

[0165] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 13 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11.

[0166] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.

[0167] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.

[0168] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.

[0169] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.

[0170] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8.

[0171] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 1, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 4, a CDR-L2 domain comprising or consistingof SEQ ID No: 5, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 7, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 8.

[0172] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.

[0173] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0174] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 or 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8.

[0175] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3.

[0176] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 4, a CDR-L2 domain comprising or consisting of SEQ ID No: 5, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3.

[0177] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 6, a CDR-L2 domaincomprising or consisting of SEQ ID No: 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 8.

[0178] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 15, and a light chain variable region comprising or consisting of SEQ ID No: 14.

[0179] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 19, or a variant or fragment thereof.

[0180] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 22, or a variant or fragment thereof.

[0181] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 19 and a light chain constant region comprising or consisting of SEQ ID No: 22.

[0182] Second antigen-binding domain (IL-23)

[0183] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27, 29 or 32, or a variant or fragment thereof.

[0184] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.

[0185] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.

[0186] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27, 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.

[0187] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.

[0188] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.

[0189] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.

[0190] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.

[0191] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0192] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0193] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.

[0194] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0195] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0196] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0197] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0198] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domaincomprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0199] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0200] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.

[0201] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.

[0202] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.

[0203] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.

[0204] A4-B4 (IL-18 WuxiBodv Regular Arm / IL-23 WuxiBodv Wuxi Arm)

[0205] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A4-B4.

[0206] First antigen-binding domain (IL-18)

[0207] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.

[0208] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.

[0209] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.

[0210] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.

[0211] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.

[0212] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.

[0213] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.

[0214] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.

[0215] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising orconsisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0216] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0217] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.

[0218] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0219] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0220] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0221] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising orconsisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0222] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0223] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.

[0224] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.

[0225] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.

[0226] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.

[0227] Second antigen-binding domain (IL-23)

[0228] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27, 29 or 32, or a variant or fragment thereof.

[0229] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.

[0230] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.

[0231] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.

[0232] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 40, or a variant or fragment thereof.

[0233] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.

[0234] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.

[0235] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.

[0236] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising orconsisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0237] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0238] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.

[0239] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0240] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0241] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0242] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domaincomprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0243] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0244] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0245] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 40, and a light chain variable region comprising or consisting of SEQ ID No: 39.

[0246] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 20, or a variant or fragment thereof.

[0247] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 23, or a variant or fragment thereof.

[0248] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 20 and a light chain constant region comprising or consisting of SEQ ID No: 23.

[0249] A5-B5 (IL-18 WuxiBodv Wuxi Arm / IL-23 WuxiBodv Regular Arm)

[0250] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A5-B5.

[0251] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.

[0252] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.

[0253] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.

[0254] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.

[0255] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.

[0256] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 16, or a variant or fragment thereof.

[0257] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.

[0258] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.

[0259] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0260] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0261] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.

[0262] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0263] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0264] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising orconsisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0265] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0266] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.

[0267] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 16, and a light chain variable region comprising or consisting of SEQ ID No: 15.

[0268] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 20, or a variant or fragment thereof.

[0269] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 23, or a variant or fragment thereof.

[0270] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 20 and a light chain constant region comprising or consisting of SEQ ID No: 23.

[0271] Second antigen-binding domain (IL-23)

[0272] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27, 29 or 32, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.

[0273] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.

[0274] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.

[0275] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.

[0276] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.

[0277] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.

[0278] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.

[0279] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0280] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0281] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.

[0282] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0283] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0284] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0285] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0286] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

[0287] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.

[0288] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.

[0289] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.

[0290] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains consisting of heavy chain variable regions comprising CDR1, CDR2, and CDR3 sequences and light chain variable regions comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 1, 4, 6, 9, 12, 24, 27, 29, 32, 33 and 36, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 2, 5, 7, 10, 13, 25, 28, 30, 34 and 37, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 3, 8, 11, 26, 31 and 35, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 9, 12, 1, 4, 6, 33, 36, 24, 27 , 29 and 32, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 10, 13, 2, 5, 7, 34, 37, 25, 28 and 30, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 11, 3, 8, 35, 26 and 31, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.

[0291] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 15, 16, 38, 39 and 40; the light chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 14, 39 and 38. Alternatively the bispecific antibody or antigen-binding fragment thereof comprises first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequenceselected from the group consisting of SEQ ID NOs: 14, 15, 16, 38, 39 and 40; the light chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 14, 39 and 38. In this context, the term "change" refers to insertions, deletions and / or substitutions.

[0292] The antibody of the invention may comprise or consist of any sequence as defined in Figure 12.

[0293] Affinity matured variants

[0294] As described in the Examples, the inventors have subjected a parent IL-18 antibody and a parent IL-23 antibody to affinity maturation in order to produce novel variants or mutants, with improved activity. The six CDR, VH, VL, CH and CL sequences of the affinity matured antibodies are summarised in the tables shown in Figure 14 (IL-18 affinity matured variants) and Figure 15 (IL-23 affinity matured variants).

[0295] Accordingly, in some embodiments, the first antigen-binding domain comprises any sequence as defined in Figure 14, and the second antigen-binding domain comprises any sequence as defined in Figure 15. For example, it will be appreciated that the IL- 18 arm ("IL-18 mAbl", or "IL-18 mAb2", etc.) shown in Figure 14, may be combined with any of the IL-23 arms shown in Figure 15, such as "IL-23 mAb 1" or "IL-23 mAb 3", etc.

[0296] In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain CDR sequences as defined in Figure 14. In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain variable sequences as defined in Figure 14. In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain constant sequences as defined in Figure 14.

[0297] In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain CDR sequences as defined in Figure 15. In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain variable sequences as defined in Figure 15. In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain constant sequences as defined in Figure 15.Figure 16 is a table showing the six CDR, VH, VL, CH and CL sequences of the first (IL-18) and second (IL-23) antigen-binding domains of the bispecific antibodies according to the invention. Accordingly, in some embodiments, the first and second antigenbinding domains comprise any of the heavy and light chain CDR sequences, any of the heavy and light chain variable sequences, and / or any of the heavy and light chain constant sequences, as defined in Figure 16.

[0298] bsAb 1

[0299] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 1. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0300] First antigen-binding domain (IL-18)

[0301] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0302] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0303] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0304] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0305] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0306] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0307] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0308] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0309] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0310] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0311] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0312] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 131, or a variant or fragment thereof.

[0313] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0314] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 131 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0315] Second antigen-binding domain (IL-23)

[0316] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0317] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0318] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0319] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0320] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0321] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0322] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0323] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0324] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0325] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0326] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0327] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0328] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0329] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0330] bsAb 2

[0331] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 2. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0332] First antigen-binding domain (IL-18)

[0333] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0334] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0335] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0336] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0337] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0338] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0339] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0340] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0341] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0342] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0343] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0344] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 131, or a variant or fragment thereof.

[0345] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0346] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 131 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0347] Second antigen-binding domain (IL-23)

[0348] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0349] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0350] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0351] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0352] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0353] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0354] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0355] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0356] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0357] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0358] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0359] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[0360] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0361] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0362] bsAb 3

[0363] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 3. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab CH-CL anti-IL-18 cross, with knob on cross arm (orientation 7 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0364] First antigen-binding domain (IL-18)

[0365] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0366] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0367] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0368] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0369] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0370] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0371] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0372] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0373] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0374] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0375] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0376] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 133, or a variant or fragment thereof.

[0377] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 134, or a variant or fragment thereof.

[0378] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 133 and a light chain constant region comprising or consisting of SEQ ID No: 134.

[0379] Second antigen-binding domain (IL-23)

[0380] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0381] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0382] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0383] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0384] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0385] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0386] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0387] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0388] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0389] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0390] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0391] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0392] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0393] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0394] bsAb 4

[0395] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 4. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab CH-CL anti-IL-18 cross, with knob on cross arm (orientation 7 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0396] First antigen-binding domain (IL-18)

[0397] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0398] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0399] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0400] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0401] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0402] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0403] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0404] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0405] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0406] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0407] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0408] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 133, or a variant or fragment thereof.

[0409] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 134, or a variant or fragment thereof.

[0410] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 133 and a light chain constant region comprising or consisting of SEQ ID No: 134.

[0411] Second antigen-binding domain (IL-23)

[0412] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0413] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0414] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0415] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0416] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0417] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0418] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0419] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0420] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0421] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0422] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0423] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[0424] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0425] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0426] bsAb 5

[0427] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 5. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.

[0428] First antigen-binding domain (IL-18)

[0429] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0430] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0431] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0432] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0433] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0434] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0435] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0436] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0437] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0438] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0439] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0440] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.

[0441] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0442] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 136 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0443] Second antigen-binding domain (IL-23)

[0444] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0445] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0446] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0447] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0448] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0449] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0450] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0451] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0452] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0453] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0454] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0455] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0456] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 135, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0457] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 135 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0458] bsAb 6

[0459] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 6. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.

[0460] First antigen-binding domain (IL-18)

[0461] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0462] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0463] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0464] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0465] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0466] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0467] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0468] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0469] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0470] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0471] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0472] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.

[0473] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0474] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 136 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0475] Second antigen-binding domain (IL-23)

[0476] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0477] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0478] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0479] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0480] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0481] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0482] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0483] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0484] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0485] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0486] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0487] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[0488] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 135, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0489] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 135 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0490] bsAb 7

[0491] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 7. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M252Y, S254T, and T256E.

[0492] First antigen-binding domain (IL-18)

[0493] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0494] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0495] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0496] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0497] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0498] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0499] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0500] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0501] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0502] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0503] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0504] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 138, or a variant or fragment thereof.

[0505] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0506] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 138 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0507] Second antigen-binding domain (IL-23)

[0508] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0509] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0510] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0511] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0512] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0513] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0514] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0515] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0516] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0517] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0518] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0519] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0520] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 137, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0521] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 137 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0522] bsAb 8

[0523] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 8. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M252Y, S254T, and T256E.

[0524] First antigen-binding domain (IL-18)

[0525] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0526] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0527] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0528] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0529] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0530] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0531] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0532] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0533] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0534] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0535] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0536] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 138, or a variant or fragment thereof.

[0537] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0538] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 138 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0539] Second antigen-binding domain (IL-23)

[0540] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0541] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0542] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0543] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0544] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0545] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0546] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0547] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0548] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0549] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0550] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0551] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[0552] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 137, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0553] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 137 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0554] bsAb 9

[0555] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 9. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M428L and N434S.

[0556] First antigen-binding domain (IL-18)

[0557] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0558] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0559] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0560] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0561] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0562] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0563] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0564] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0565] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0566] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0567] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0568] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.

[0569] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0570] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 140 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0571] Second antigen-binding domain (IL-23)

[0572] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0573] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0574] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0575] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0576] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0577] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0578] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0579] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0580] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0581] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0582] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0583] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0584] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 139, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0585] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 139 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0586] bsAb 10

[0587] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 10. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M428L and N434S.

[0588] First antigen-binding domain (IL-18)

[0589] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0590] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0591] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0592] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0593] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0594] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0595] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0596] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0597] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0598] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0599] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0600] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.

[0601] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0602] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 140 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0603] Second antigen-binding domain (IL-23)

[0604] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0605] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0606] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0607] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0608] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0609] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0610] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0611] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0612] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0613] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0614] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0615] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[0616] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 139, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0617] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 139 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0618] bsAb 11

[0619] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 11. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M428L and N434S.

[0620] First antigen-binding domain (IL-18)

[0621] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0622] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0623] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0624] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0625] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0626] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0627] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0628] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0629] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0630] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0631] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0632] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.

[0633] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0634] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 142 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0635] Second antigen-binding domain (IL-23)

[0636] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0637] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0638] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0639] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0640] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0641] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0642] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0643] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0644] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0645] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0646] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0647] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0648] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0649] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 141 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0650] bsAb 12

[0651] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 12. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M428L and N434S.

[0652] First antigen-binding domain (IL-18)

[0653] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0654] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0655] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0656] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0657] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0658] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0659] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0660] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0661] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0662] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0663] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0664] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.

[0665] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0666] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 142 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0667] Second antigen-binding domain (IL-23)

[0668] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0669] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0670] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0671] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0672] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0673] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0674] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0675] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0676] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0677] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0678] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0679] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[0680] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0681] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 141 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0682] bsAb 13

[0683] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 13. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LAGA YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L235A and G237A and / or M252Y, S254T, and T256E.

[0684] First antigen-binding domain (IL-18)

[0685] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0686] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0687] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0688] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0689] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0690] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0691] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0692] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0693] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0694] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0695] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0696] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 144, or a variant or fragment thereof.

[0697] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0698] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 144 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0699] Second antigen-binding domain (IL-23)

[0700] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0701] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0702] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0703] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0704] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0705] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0706] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0707] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0708] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0709] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0710] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0711] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0712] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 143, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0713] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 143 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0714] bsAb 14

[0715] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 14. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LAGA YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L235A and G237A and / or M252Y, S254T, and T256E.

[0716] First antigen-binding domain (IL-18)

[0717] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0718] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0719] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0720] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0721] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0722] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0723] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0724] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0725] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0726] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0727] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0728] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 144, or a variant or fragment thereof.

[0729] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0730] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 144 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0731] Second antigen-binding domain (IL-23)

[0732] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0733] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0734] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0735] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0736] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0737] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0738] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0739] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0740] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0741] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0742] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0743] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[0744] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 143, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0745] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 143 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0746] bsAb 15

[0747] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 15. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-23 cross, with knob on cross arm (orientation 1 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0748] First antigen-binding domain (IL-18)

[0749] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0750] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0751] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0752] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0753] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0754] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0755] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0756] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0757] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0758] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0759] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0760] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.

[0761] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0762] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0763] Second antigen-binding domain (IL-23)

[0764] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.

[0765] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0766] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0767] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 126 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.

[0768] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0769] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0770] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0771] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0772] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0773] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0774] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 126, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0775] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 127, and a light chain variable region comprising or consisting of SEQ ID No: 124.

[0776] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 131, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0777] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 131 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0778] bsAb 16

[0779] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 16. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-23 cross, with hole on cross arm (orientation 2 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0780] First antigen-binding domain (IL-18)

[0781] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0782] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0783] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0784] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0785] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0786] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0787] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0788] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0789] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0790] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0791] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0792] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 146, or a variant or fragment thereof.

[0793] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0794] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 146 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0795] Second antigen-binding domain (IL-23)

[0796] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.

[0797] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0798] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0799] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 126 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.

[0800] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0801] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0802] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0803] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0804] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0805] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0806] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 126, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0807] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 127, and a light chain variable region comprising or consisting of SEQ ID No: 124.

[0808] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 145, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0809] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 145 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0810] bsAb 17

[0811] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 17. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with hole on cross arm (orientation 4 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0812] First antigen-binding domain (IL-18)

[0813] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0814] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0815] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0816] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[0817] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0818] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0819] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0820] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0821] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[0822] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0823] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[0824] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 145, or a variant or fragment thereof.

[0825] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0826] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 145 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0827] Second antigen-binding domain (IL-23)

[0828] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0829] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0830] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0831] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0832] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0833] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0834] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0835] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0836] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0837] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0838] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0839] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0840] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 146, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0841] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 146 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0842] bsAb 18

[0843] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 18. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab CH-CL anti-IL-23 cross, with knob on cross arm (orientation 5 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0844] First antigen-binding domain (IL-18)

[0845] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0846] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0847] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0848] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0849] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0850] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0851] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0852] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0853] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0854] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0855] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0856] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.

[0857] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0858] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0859] Second antigen-binding domain (IL-23)

[0860] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0861] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0862] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0863] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0864] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0865] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0866] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0867] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0868] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0869] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0870] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0871] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0872] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 133, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 134, or a variant or fragment thereof.

[0873] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 133 and a light chain constant region comprising or consisting of SEQ ID No: 134.

[0874] bsAb 19

[0875] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 19. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab CH-CL anti-IL-23 cross, with hole on cross arm (orientation 6 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0876] First antigen-binding domain (IL-18)

[0877] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0878] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0879] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0880] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0881] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0882] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0883] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0884] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0885] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0886] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0887] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0888] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 148, or a variant or fragment thereof.

[0889] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0890] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 148 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0891] Second antigen-binding domain (IL-23)

[0892] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0893] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0894] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0895] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0896] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0897] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0898] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0899] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0900] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0901] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0902] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0903] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0904] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 147, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 134, or a variant or fragment thereof.

[0905] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 147 and a light chain constant region comprising or consisting of SEQ ID No: 134.

[0906] bsAb 20

[0907] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 20. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab CH-CL anti-IL-18 cross, with hole on cross arm (orientation 8 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0908] First antigen-binding domain (IL-18)

[0909] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0910] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0911] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0912] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0913] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0914] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0915] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0916] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0917] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0918] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0919] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0920] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 147, or a variant or fragment thereof.

[0921] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 134, or a variant or fragment thereof.

[0922] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 147 and a light chain constant region comprising or consisting of SEQ ID No: 134.

[0923] Second antigen-binding domain (IL-23)

[0924] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[0925] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0926] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0927] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[0928] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0929] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 126, or a variant or fragment thereof.

[0930] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0931] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0932] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 127, or a variant or fragment thereof.

[0933] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0934] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[0935] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127.

[0936] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 146, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0937] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 146 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0938] bsAb 21

[0939] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 21. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-23 cross, with knob on cross arm (orientation 1 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0940] First antigen-binding domain (IL-18)

[0941] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0942] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0943] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0944] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0945] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0946] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0947] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0948] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0949] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0950] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0951] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0952] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.

[0953] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0954] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0955] Second antigen-binding domain (IL-23)

[0956] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.

[0957] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0958] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0959] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 128 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.

[0960] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0961] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0962] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0963] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0964] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0965] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0966] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 128, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0967] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 129, and a light chain variable region comprising or consisting of SEQ ID No: 124.

[0968] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 131, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[0969] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 131 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[0970] bsAb 22

[0971] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 22. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-23 cross, with hole on cross arm (orientation 2 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[0972] First antigen-binding domain (IL-18)

[0973] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[0974] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[0975] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[0976] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[0977] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[0978] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[0979] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[0980] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0981] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[0982] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0983] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[0984] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 146, or a variant or fragment thereof.

[0985] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[0986] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 146 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[0987] Second antigen-binding domain (IL-23)

[0988] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.

[0989] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[0990] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[0991] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 128 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.

[0992] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[0993] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[0994] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[0995] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0996] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[0997] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[0998] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 128, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

[0999] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 129, and a light chain variable region comprising or consisting of SEQ ID No: 124.

[1000] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 145, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[1001] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 145 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[1002] bsAb 23

[1003] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 23. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab VH-VL anti-IL-18 cross, with hole on cross arm (orientation 4 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[1004] First antigen-binding domain (IL-18)

[1005] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[1006] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[1007] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[1008] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.

[1009] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[1010] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[1011] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[1012] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[1013] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.

[1014] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[1015] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.

[1016] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 145, or a variant or fragment thereof.

[1017] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 132, or a variant or fragment thereof.

[1018] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 145 and a light chain constant region comprising or consisting of SEQ ID No: 132.

[1019] Second antigen-binding domain (IL-23)

[1020] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[1021] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[1022] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[1023] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[1024] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[1025] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[1026] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[1027] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[1028] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[1029] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[1030] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[1031] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[1032] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 146, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[1033] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 146 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[1034] bsAb 24

[1035] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 24. It will be appreciated that this antibody is an anti-IL-18xIL-23 CrossMab CH-CL anti-IL-23 cross, with knob on cross arm (orientation 5 shown in Figure 13, with the FES mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S.

[1036] First antigen-binding domain (IL-18)

[1037] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.

[1038] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.

[1039] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.

[1040] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.

[1041] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 49, or a variant or fragment thereof.

[1042] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.

[1043] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.

[1044] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[1045] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 52, or a variant or fragment thereof.

[1046] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[1047] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.

[1048] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52.In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 130, or a variant or fragment thereof.

[1049] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.

[1050] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 130 and a light chain constant region comprising or consisting of SEQ ID No: 53.

[1051] Second antigen-binding domain (IL-23)

[1052] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.

[1053] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.

[1054] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 123, or a variant or fragment thereof.

[1055] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 123.

[1056] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 124, or a variant or fragment thereof.

[1057] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 128, or a variant or fragment thereof.

[1058] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

[1059] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[1060] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 129, or a variant or fragment thereof.

[1061] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.

[1062] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.

[1063] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129.

[1064] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 133, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 134, or a variant or fragment thereof.

[1065] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 133 and a light chain constant region comprising or consisting of SEQ ID No: 134.

[1066] bsAb 25

[1067] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as bsAb 25. It will be appreciated that ...

Claims

Claims1. A bispecific antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to Interleukin-18 (IL-18) or a functional fragment or variant thereof, and a second antigen-binding domain that specifically binds to Interleukin-23 (IL-23) or a functional fragment or variant thereof.

2. The bispecific antibody or antigen-binding fragment thereof according to claim 1, wherein the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 42 and / or SEQ ID No: 43, or a functional fragment or variant thereof.

3. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2:(a) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(b) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 49, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(c) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 126, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(d) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 123, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 128, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121;(e) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 126, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 123; or(f) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 49, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising orconsisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 128, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 123.

4. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

5. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27, 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.

6. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising orconsisting of SEQ ID No: 10 or 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.

7. The bispecific antibody or antigen-binding fragment thereof according to claim 3:(a) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127;(b) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 52, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129;(c) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 127;(d) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 124, and a light chain variable region comprising or consisting of SEQ ID No: 129;(e) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ IDNo: 127, and a light chain variable region comprising or consisting of SEQ ID No: 124; or(f) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 52; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 129, and a light chain variable region comprising or consisting of SEQ ID No: 124.

8. The bispecific antibody or antigen-binding fragment thereof according to claim 4, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.

9. The bispecific antibody or antigen-binding fragment thereof according to claim 5, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 39, and a light chain variable region comprising or consisting of SEQ ID No: 38.

10. The bispecific antibody or antigen-binding fragment thereof according to claim 6, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 15, and a light chain variable region comprising or consisting of SEQ ID No: 14; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.

11. The bispecific antibody or antigen-binding fragment thereof according to claim 4, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 40, and a light chain variable region comprising or consisting of SEQ ID No: 39.

12. The bispecific antibody or antigen-binding fragment thereof according to claim 4, wherein (i) the first antigen-binding domain comprises a heavy chain variableregion comprising or consisting of SEQ ID No: 16, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.

13. The bispecific antibody or antigen-binding fragment thereof according to any preceding claim, wherein the bispecific antibody or antigen-binding fragment thereof comprises a mutated Fc fragment, optionally wherein:(i) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234A, L235A, and P329G, according to EU numbering;(ii) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: N325S and L328F, according to EU numbering;(iii) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M252Y, S254T, and T256E, according to EU numbering;(iv) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234F, L235E and P331S, according to EU numbering;(v) the Fc fragment of the first or second antigen-binding domain comprises a T366W amino acid substitution, and the Fc fragment of the first or second antigenbinding domain comprises the amino acid substitutions T366S, L368A, and Y407V, according to EU numbering; and / or(vi) the Fc fragment of the first or second antigen-binding domain comprises a F405L amino acid substitution, and the Fc fragment of the first or second antigenbinding domain comprises a K409R amino acid substitution, according to EU numbering.

14. An antibody or antigen-binding fragment thereof that specifically binds to IL-18, and comprises:(i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, 80, 84, 101, or 104, or a variant or fragment thereof;(ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 45, 58, 62, 64, 68, 70, 72, 78, 82, 86, 88, 90, or 102, or a variant or fragment thereof;(iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 46, 60, or 106, or a variant or fragment thereof;(iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 49, 54, 56, or 74, or a variant or fragment thereof;(v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 50, 66, or 93, or a variant or fragment thereof; and / or(vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 51, 76, 94, or 108, or a variant or fragment thereof.

15. The antibody or antigen-binding fragment thereof according to claim 14, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 47, 59, 61, 63, 65, 69, 71, 73, 79, 81, 83, 85, 87, 89, 91, 92, 97, 99, 103, 105, 107, 110, 112, 113, or 117, and a light chain variable region comprising or consisting of any one of SEQ ID Nos: 52, 55, 57, 67, 75, 77, 95, 96, 100, 109, or 111.

16. An antibody or antigen-binding fragment thereof that specifically binds to IL-23, and comprises:(i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof;(ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof;(iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 116 or 123, or a variant or fragment thereof;(iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof;(v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 120, 126, or 128, or a variant or fragment thereof; and / or(vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.

17. The antibody or antigen-binding fragment thereof according to claim 18, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 117 or 124, and alight chain variable region comprising or consisting of any one of SEQ ID Nos: 122, 127 or 129.

18. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in therapy.

19. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in treating, preventing or ameliorating a condition mediated by IL-18 and / or IL-23.

20. The bispecific antibody or antigen-binding fragment thereof, or the antibody or antigen-binding fragment thereof, for use according to claim 19, wherein the condition mediated by IL-18 and / or IL-23 is selected from the group consisting of: Inflammatory Bowel Disease (IBD) including Crohn's Disease and Ulcerative Colitis, Psoriasis, Psoriatic Arthritis, Hidradenitis Suppurativa (HS), Ankylosing Spondylitis (AS), Multiple Sclerosis (MS), Uveitis, Atopic Dermatitis (AD), Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still's Disease (AOSD), Macrophage Activation Syndrome (MAS), Hemophagocytic Lymphohistiocytosis (HLH), Neuroinflammation, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Infections, Sepsis, and Cytokine Storm Syndromes.

21. A pharmaceutical composition comprising the bispecific antibody or antigenbinding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, and optionally a pharmaceutically acceptable vehicle.

22. A process for making the pharmaceutical composition according to claim 21, the process comprising combining a therapeutically effective amount of the bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, with a pharmaceutically acceptable vehicle.

23. One or more polynucleotide sequence encoding the bispecific antibody or antigen binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17.

24. An expression cassette comprising one or more polynucleotide sequence according to claim 23.

25. A recombinant vector comprising the expression cassette according to claim 24.

26. A host cell comprising the one or more polynucleotide sequence according to claim 23, the expression cassette according to claim 24, or the vector according to claim 25.

27. A method of preparing the bispecific antibody or antigen binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, the method comprising:a) introducing, into a host cell, the vector of claim 25; andb) culturing the host cell under conditions to result in the production of the bispecific antibody or antigen binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17.

28. The bispecific antibody or antigen-binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in diagnosis or prognosis.

29. The bispecific antibody or antigen-binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17, for use in diagnosing or prognosing a condition mediated by IL-18 and / or IL-23.

30. A method of diagnosing or prognosing a condition mediated by IL-18 and / or IL-23 in a subject, the method comprising detecting IL-18 and / or IL-23 in a biological sample obtained from the subject with the bispecific antibody or antigen-binding fragment according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to any one of claims 14 to 17.

31. A kit for diagnosing a subject suffering from a condition mediated by IL-18 and / or IL-23, or for providing a prognosis of the subject's condition, the kit comprising the bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or the antibody or antigen-binding fragment thereof according to anyone of claims 14 to 17, for detecting IL-18 and / or IL-23 in a sample from a test subject.